Movement Alert|Innovent Biologics Rises 3.07% in Regular Trading, Biotech Sector Rally and EULAR Conference Data Provide Dual Catalysts

Market Focus
06/18

On June 18, Innovent Biologics rose 3.07% in regular trading, trading at 77.75 HKD/share, with turnover of approximately 175 million HKD.

On the news front, the biotechnology sector rallied broadly, with AKESO up 6.91%, 3SBIO up 5.04%, Remegen up 4.75%, BeiGene up 4.70%, and SKB Bio up 4.66%, forming strong sector-wide momentum that lifted Innovent Biologics. Additionally, the ongoing EULAR rheumatology conference recently disclosed clinical data on immune resetting therapies for autoimmune diseases, providing academic catalysts for companies with rich autoimmune pipelines. Innovent Biologics, which maintains an extensive portfolio spanning oncology, cardiovascular and metabolic diseases, and autoimmune conditions, stands to benefit from renewed investor interest in the autoimmune therapeutic space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10